Fluvoxamine and Ivermectin: Early treatment for COVID-19 is key to better outcomes (May 2022)

Although the vaccine rollout is greatly reducing the number of people who get seriously ill and are hospitalized with COVID-19, no vaccine offers 100% protection, and new mutations and variants of the virus such as Delta and Omicron are appearing all the time. So it's still important to find new treatments for the illness. In this article, we will cover 2 popular treatments i.e. Fluvoxamine and Ivermectin. Fluvoxamine One of them, the generic drug fluvoxamine, has shown huge potential. Developed 40 years ago as an antidepressant, fluvoxamine—sometimes known as Luvox (brand name) - has been used mainly to treat obsessive-compulsive disorder (OCD), per the National Alliance on Mental Illness (NAMI). But now, researchers are taking a closer look at how the medication could be an important treatment to prevent patients who test positive for COVID-19 from getting seriously ill with the infection. TreatEarly.org In May 2022, the Food and Drug Administration denied an emergency use